A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

59 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-09-30

Study Completion Date

2010-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the safety and side effects of multiple doses of LY2541546 in postmenopausal women when given subcutaneously (injection just under the skin) and intravenously (directly into a vein). The study will also test how long it takes the study drug to get into the body, how long it takes the body to get rid of it, the overall effect of the study drug on the body, and whether antibodies to the study drug are formed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY2541546 in Healthy Postmenopausal Women

NCT01742078

Healthy

COMPLETED PHASE1

A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women

NCT02337387

Osteoporosis, Postmenopausal

TERMINATED PHASE1

A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women

NCT06908707

Postmenopausal Healthy Adult Female Participants

COMPLETED PHASE1

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

NCT00331214

Hypoactive Sexual Desire Disorder

COMPLETED PHASE3

Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

NCT00808132

Menopause Osteoporosis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

180 mg LY2541546 SC Q4W

180 milligram (mg) LY2541546 administered subcutaneous (SC) once every 4 weeks (Q4W) for 8 weeks. Placebo administered SC at Weeks 2 and 6 to maintain the blind.

Group Type EXPERIMENTAL

LY2541546 - SC

Intervention Type DRUG

Administered SC

Placebo - SC

Intervention Type DRUG

Administered SC

270 mg LY2541546 SC Q2W

270 mg LY2541546 administered (SC) once every 2 weeks (Q2W) for 8 weeks.

Group Type EXPERIMENTAL

LY2541546 - SC

Intervention Type DRUG

Administered SC

270 mg LY2541546 SC Q4W

270 mg LY2541546 administered (SC) once every 4 weeks (Q4W) for 8 weeks. Placebo administered SC at Weeks 2 and 6 to maintain the blind.

Group Type EXPERIMENTAL

LY2541546 - SC

Intervention Type DRUG

Administered SC

Placebo - SC

Intervention Type DRUG

Administered SC

540 mg LY2541546 IV Q4W

540 mg administered intravenous (IV) once every 4 weeks (Q4W) for 8 weeks. Placebo administered IV at Weeks 2 and 6 to maintain the blind.

Group Type EXPERIMENTAL

LY2541546 - IV

Intervention Type DRUG

Administered IV

Placebo - IV

Intervention Type DRUG

Administered IV

750 mg LY2541546 IV Q2W

750 mg administered (IV) once every 2 weeks (Q2W) for 8 weeks.

Group Type EXPERIMENTAL

LY2541546 - IV

Intervention Type DRUG

Administered IV

Placebo Q2W

Placebo administered IV or SC once every 2 weeks for 8 weeks.

Group Type PLACEBO_COMPARATOR

Placebo - SC

Intervention Type DRUG

Administered SC

Placebo - IV

Intervention Type DRUG

Administered IV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY2541546 - SC

Administered SC

Intervention Type DRUG

LY2541546 - IV

Administered IV

Intervention Type DRUG

Placebo - SC

Administered SC

Intervention Type DRUG

Placebo - IV

Administered IV

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Blosozumab Blosozumab

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy postmenopausal females, as determined by medical history and physical examination
* Body mass index (BMI) at screening between 19.0 and 32.0 kilograms per square meter (kg/m\^2), inclusive
* Acceptable clinical laboratory test results, blood pressure and heart rate
* Have given written informed consent

Exclusion Criteria

* Within 30 days of the initial dose of study drug, have received treatment with a drug that has not received regulatory approval for any indication
* Have received study treatment in any trial of an investigational osteoporosis treatment, including LY2561553 (parathyroid hormone receptor modulator), within 12 weeks of screening or 5 half-lives, whichever is longer
* Known allergies to LY2541546, its constituents, or related compounds
* Persons who have previously participated in this study or any other study of LY2541546
* History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders
* History or presence of low platelet count, bleeding issues or family history of bleeding disorders
* Paget's disease, parathyroid disease, or thyroid disease
* Fracture of a long bone within 12 weeks of screening
* Regular use of known drugs of abuse and/or positive findings on urinary drug screening
* Evidence of human immunodeficiency virus (HIV), hepatitis C, hepatitis B and/or positive for anti-HIV antibodies, hepatitis C antibody, or hepatitis B surface antigen
* Current use of therapies for osteoporosis or use of hormone replacement therapy (HRT) within the previous 12 months
* Blood donation within the last month
* Are unwilling or unable to maintain their normal pattern of alcohol, caffeine, smoking, and exercise from the start to the end of the study or to abide by the clinical research unit restrictions. Note: Average weekly alcohol intake must not exceed 14 units per week
* Are unable or unwilling to refrain from nicotine usage during Clinical Research Unit (CRU) confinement

Minimum Eligible Age

45 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes